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Objective rheumatoid arthritis (ra) is a systemic, 
immune-mediated inflammatory disease that ultimately 
leads to bone erosions and joint destruction. Methotrexate 
(MtX) slows bone damage but the mechanism by 
which it acts is still unknown. in this study, we aimed 
to assess the effect of MtX and low-dose prednisolone 
(PDn) on circulating osteoclast (Oc) precursors and Oc 
differentiation in patients with ra.
Methods Patients with ra before and at least 6 months 
after MtX therapy were analysed and compared with 
healthy donors. a blood sample was collected in order to 
assess receptor activator of nF-κβ (ranK) ligand surface 
expression on circulating leucocytes and frequency and 
phenotype of monocyte subpopulations. Quantification of 
serum levels of bone turnover markers and cytokines and 
Oc differentiation assays were performed.
Results classical activation markers of monocytes 
and ranK increased in patients with ra at baseline, 
compared with control healthy donors, and after MtX 
and low-dose PDn (MtX+PDn) exposure they decreased 
to control levels. although the number of Oc was not 
different between groups, the percentage of resorbed 
area and the resorbed area per pit reduced after 
treatment. Serum soluble receptor activator of nuclear 
factor-kappa (ranKl) levels increased at baseline 
compared with healthy donors and normalised after 
therapy.
Conclusion Our results suggest that MtX+PDn play an 
important role in downregulating Oc function, which we 
believe occurs through the decrease in ranK surface 
expression in monocytes.
Rheumatoid arthritis (RA) is a chronic, 
immune-mediated, inflammatory disease that 
mainly impacts joints. It affects around 1% 
of the world population and the majority of 
the affected patients are women.1 The main 
features of RA are synovial hyperplasia with 
pannus formation and bone erosions. On the 
other hand, systemic inflammation leads also 
to secondary osteoporosis and bone fragility.2 
In RA, there is an imbalance between bone 
formation and bone resorption. In fact, the 
immune system contributes directly to bone 
resorption by producing receptor activator 
of NF-κβ (RANK) ligand and indirectly 
through the secretion of pro-inflammatory 
cytokines that act synergistically with the 
RANK-RANKL system, further enhancing 
osteoclast (OC) differentiation and bone 
resorption.3 Monocytes are OC precursors; 
these cells have phenotypical and functional 
heterogeneity and have a critical regulatory 
role in inflammation and innate immune 
response.4 5 Monocytes can be subdivided 
into three subpopulations based on their 
Key messages
What is already known about this subject?
 ► Methotrexate slows bone damage but the 
mechanism by which it acts is still unknown.
What does this study add?
 ► Methotrexate  and low-dose corticosteroids 
downregulate osteoclast function through the 
decrease of  receptor activator of nF-κB  surface 
expression in monocytes.
How might this impact on clinical practice?
 ► these observations reinforce the relevance of early 
treatment intervention in early ra with low-dose 
prednisolone and methotrexate.
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expression of CD14 and CD16 surface markers: the clas-
sical (CD14brightCD16−), intermediate (CD14brightCD16+) 
and non-classical (CD14dimCD16+) subsets.4 All of these 
precursors are able to differentiate into OC increasing 
bone resorption.6 7 Moreover, in RA, CD14+ monocytes 
continuously migrate into the injured joint tissues where 
they are activated and act as local and systemic amplifiers 
of the disease through a multitude of mediators.8–10
Methotrexate (MTX) combined with low-dose 
prednisolone (PDN) is the cornerstone of early RA treat-
ment, reducing inflammation and slowing down bone 
damage.11–14 A recent report depicted that OC formation 
and OC gene expression, such as NFATc1 and DC-STAMP, 
which are induced by the cytokine RANKL, are signifi-
cantly inhibited by MTX.15 In this study, we aimed to 
assess the effect of MTX and low-dose PDN (MTX+PDN) 
on the circulating OC precursors and OC differentiation 
in patients with RA.
Patients and methods
Patients
Patients with early untreated RA (<12 months of disease 
duration) fulfilling the American College of Rheuma-
tology/European League Against Rheumatism criteria, 
201016 were recruited from the Rheumatology and 
Bone Metabolic Disease Department, Hospital de Santa 
Maria, Lisbon Academic Medical Centre, Portugal. All 
patients included were naïve to disease-modifying anti-
rheumatic drugs (DMARDs) and corticoids and were 
followed in the outpatient clinic during a minimum of 
6 months after starting MTX+PDN treatment. Moder-
ate-to-high disease activity was required for inclusion, 
defined as disease activity score 28 (DAS28) >3.2.17 
Patients previously exposed or actively under corticoids 
and/or DMARD therapy were excluded from this study. 
The use of non-steroidal anti-inflammatory drugs was not 
an exclusion criterion. Information regarding patients' 
demographics, duration of symptoms, erythrocyte sedi-
mentation rate (ESR), C reactive protein (CRP), tender 
and swollen joints counts, presence of erosions, presence 
of rheumatoid factor (RF) and presence of anticitrulli-
nated protein antibodies was collected. Both DAS28 and 
the Health Assessment Questionnaire18 were applied to 
patients. Patients with RA were managed by the stan-
dard-of-care approach, with no deviation induced by the 
participation in this study.
Heparinised blood and serum were collected from 
each participant at the starting of MTX and prednisolone 
and after 6 months of reaching the minimum effective 
dose of MTX. Blood was used for flow cytometry and 
peripheral blood mononuclear cell (PBMC) isolation. 
Healthy donors matched for age and gender were used 
as controls. The local ethics committee approved this 
study and all participants signed an informed consent. 
Patients were managed in accordance with the standard 
practice and the study was conducted in accordance with 
the Declaration of Helsinki as amended in Brazil (2013).
antibodies and flow cytometry
Identification of B and T cells and neutrophils in 
peripheral blood and immunophenotyping of mono-
cytes in the PBMC samples were performed using 
matched combinations of antihuman murine mono-
clonal antibodies. For peripheral blood staining, 
anti-CD19 PerCP-Cy5.5 (eBioscience, San Diego, 
California, USA), anti-CD3 PerCP (BD Biosciences, 
Franklin Lakes, New Jersey, USA), anti-CD66b FITC 
(Immunotools, Friesoythe, Germany) and anti-RANKL 
PE (Santa Cruz Biotechnology, Dallas, Texas, USA) 
were used. Monocyte subpopulations were identified 
with anti-CD14 FITC (BD Biosciences) or PerCPCy5.5 
(Immunotools) and anti-CD16 APC (Immunotools) 
and stained with combinations of anti-CD11b PE-Cy7, 
CD105 PE, CD62L PE-Cy7, CD51/CD61 FITC (eBio-
science), CCR2 PE (R&D Systems, Minneapolis, 
Minnesota, USA), human leucocyte antigen - antigen D 
related (HLA)-DR PerCP (BD Biosciences) and RANK 
PE (Santa Cruz Biotechnology). Cell death was assessed 
by staining with Annexin V Apoptosis Detection Kit 
APC (eBioscience). Acquisition was performed using a 
FACSCalibur (BD Biosciences).
Heparinised whole blood was used for staining. Eryth-
rocytes were lysed with red blood cell lysis buffer and 
cells were incubated with IgG block solution 300 ng/
mL (ChromPure Mouse IgG whole molecule, Jackson 
ImmunoResearch Laboratories, West Grove, Pennsyl-
vania, USA) before staining. Absolute cell counts were 
calculated from differential leucocyte count deter-
mined for all participants. PBMCs were isolated by 
density gradient centrifugation with Histopaque−1077 
(Sigma-Aldrich, St. Louis, Missouri, USA). Monocyte 
subpopulations were identified as described before 
based on their CD14 and CD16 surface expression.4 
Data were analysed using FlowJo software (TreeStar, 
Stanford University, Stanford, California, USA).
osteoclast differentiation
PBMCs isolated by density gradient centrifugation were 
plated in 96-well culture plates as described before.19 
PBMCs were left overnight for osteoclast precursors 
(OCPs) to adhere on bone slices (Immunodiagnostic 
Systems, Boldon, UK).20 On the following day (day 
1 of culture), medium was changed to Dulbecco's 
modified Eagle's Medium (DMEM) supplemented 
with macrophage colony stimulating factors (M-CSF) 
25 ng/mL (Peprotech, London, UK). Three days later, 
medium was again changed to DMEM with M-CSF 
(25 ng/mL), soluble RANKL (sRANKL) (50 ng/mL; 
Peprotech), dexamethasone (10 nM; Sigma-Aldrich) 
and transforming growth factor β (2.5 ng/mL; R&D 
Systems) in order to differentiate the OCPs into 
mature OC.21 The culture medium was then changed 
twice a week. Cells cultured on bone slices for 7, 14 
and 21 days20 22 were used for functional assays and 
gene expression.
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Functional assays
TRAP staining of OC was performed using the Acid 
Phosphate, Leukocyte Kit (tartrate resistant acid phos-
phatase (TRAP), Sigma-Aldrich) according to the 
manufacturer's instructions. This assay allows the iden-
tification of mature OC (TRAP-positive cells containing 
three or more nuclei). In the resorption assay, to measure 
the resorbed area, OC were removed from the bone 
slices using sodium hypochlorite and stained with 0.1% 
toluidine blue.
Bone slices from both TRAP staining and resorp-
tion functional assays were photographed in an area of 
1.25 mm2 with a brightfield microscope (Leica DM2500, 
Leica, Wetzlar, Germany) under a 10x objective. The 
number of TRAP-stained OC was counted for each time-
point per condition and the resorption pits were traced 
using ImageJ (NIH, Bethesda, Maryland, USA), a mean 
value of the resorbed area was calculated and expressed 
in percentage of total area.
Bone turnover markers detection
Serum sRANKL and osteoprotegerin (OPG) were quan-
tified by ELISA (Biomedica Grouppe, Vienna, Austria) 
according to the manufacturer’s instructions.
statistical analysis
Statistical analysis was performed with SPSS Statistics 
V.17.0 (IBM, Portsmouth, UK). Categorical variables 
were expressed as frequencies and comparisons were 
tested using χ2 test. Continuous variables were expressed 
by median and IQR. Before and after treatment values 
within each sample were compared using Wilcoxon's 
matched-pairs signed-rank test. To compare patients 
with RA with healthy age-matched and sex-matched 
donors, Mann-Whitney U test was used. Clinical vari-
ables such as DAS28, CRP, ESR and tender and joint 
count were correlated with OC activation parameters 
(pit number and carboxy-terminal telopeptide of type I 
collagen (CTX-I)) using Spearman's correlation; p values 
<0.05 were considered to be statistically significant.
Results
Population characteristics
This study was conducted in 14 untreated patients with 
early RA, before and after initiation of combined MTX 
and PDN treatment, and in 18 age-matched and gender-
matched healthy donors. All patients had <12 months 
disease duration and were corticosteroid and synthetic 
DMARD naïve at baseline. The clinical and demographic 
features of patients before and after treatment and of 
the healthy donors are described in table 1. All patients 
were under MTX (mean dose of 15 mg/week) and 
prednisolone (<10 mg/day). To three patients hydroxy-
chloroquine (400 mg/day) was added later on and two 
patients received concomitant sulfasalazine (2 g/day), 
due to incomplete response to MTX. Patients' median 
Table 1 Summary of patients and healthy controls' characteristics
Patients with RA h
Healthy p ValueBaseline Treated
Sample size 14 18
Age (years) 50 (32–60) 44 (36–52) 0.50853
Females (n, %) 10, 71% 11, 61% 0.7120
Symptoms duration (months) 9 (2–12) NA
RF (n positive, % positive) 8, 57% NA
ACPA (n positive, % positive) 5, 36% NA
Erosive (n positive, % yes) 3, 21% NA
Treatment with NSAID (n, %) 8, 57% NA
NSAIDs duration (months) 2.3 (0.3–5.5) NA
Treatment with MTX (%) 0% 100%*
ESR (mm/hour) 22 (11–44) 13 (9–27) NA 0.1934
CRP (mg/dL) 0.3 (0.1–2.7) 0.2 (0.1–0.3) NA 0.1289
Tender joint count 4 (0–7) 0 (0–1) NA 0.3738
Swollen joint count 6 (2–10) 1 (0–1) NA 0.0380*
DAS28 4.7 (4.2–5.4) 2.4 (2.1–3.6) NA 0.0137*
HAQ 1.4 (0.6–2.2) 0.3 (0.0–0.7) NA 0.1250
*All patients were under MTX and prednisolone. To three patients hydroxychloroquine was added later on and two patients received 
concomitant sulfasalazine. *p<0.05 between patients before and after treatment with MTX.
Data are represented as median and IQR unless stated otherwise.
RA, rheumatoid arthritis; NA, not applicable; RF, rheumatoid factor; ACPA, anticitrullinated protein antibodies; NSAIDs, non-steroidal anti-
inflammatory drugs; MTX, methotrexate; ESR, erythrocyte sedimentation rate; CRP, C reactive protein; DAS, disease activity score; HAQ, 
Health Assessment Questionnaire.
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MTX therapy duration was 13 months (minimum 6 and 
maximum 24 months).
Patients with Ra had a higher number of neutrophils 
expressing RanKl than controls, which regressed to control 
levels after treatment
The number of neutrophils was significantly higher in 
patients with RA at baseline when compared with healthy 
donors (both frequency p=0.0110 and absolute number 
p=0.0032; figure 1). Moreover, the absolute number of 
neutrophils expressing RANKL on their surface was also 
higher than in controls (p=0.0060). After treatment, the 
absolute counts of neutrophils decreased (p=0.0155). No 
difference was found in the total number of circulating 
T or B cells before and after therapy or when compared 
with healthy donors (data not shown). Moreover, no 
differences were found regarding RANKL surface expres-
sion on neutrophils, T and B cells.
treatment reduced RanK expression in monocyte 
subpopulations in patients with Ra
Regarding the monocyte subpopulations (classical 
CD14brightCD16−, intermediate CD14brightCD16+ and 
non-classical CD14dimCD16+), no differences in frequency 
or cell death among the three subpopulations or between 
groups were found (data not shown).
In patients with RA at baseline, CCR2 expression was 
higher both in the classical and intermediate subpop-
ulations (p=0.0120 and p=0.0471 when compared with 
controls; figure 2) and decreased after therapy (p=0.0039 
for classical and p=0.0237). HLA-DR and CD86 expres-
sion were also higher in the classical subpopulation of 
patients with RA at baseline (p=0.0002 and p=0.0068) 
as compared with controls. However, while HLA-DR 
expression remained elevated after treatment (p=0.0006 
compared with controls), CD86 expression decreased 
(p=0.0237). RANK expression was higher than in controls, 
both in the intermediate and non-classical subpopula-
tions (p=0.0112 and p=0.0475, respectively), while CD51/
CD61 (αVβ3 integrin) was higher in the intermediate 
subpopulation (p=0.0487) and CD11b in the non-classical 
subpopulation (p=0.0160) as compared with controls. 
Treatment with MTX+PDN decreased RANK and CD11b 
in the intermediate (p=0.0234 and p=0.0125) and 
non-classical subpopulations (p=0.0084 and p=0.0132) 
and CD11b in the classical subpopulation (p=0.0091).
in vitro assays showed that oCs from patients with Ra 
at baseline are more active than the ones from treated 
patients and controls
The number of OC increased in all groups throughout 
culture time. No significant differences in OC number/
mm2 or pit number were found (figure 3). However, the 
percentage of resorbed area was higher in patients with 
RA at baseline at culture days 14 and 21 when compared 
with controls (p=0.0333 and p=0.0436). Resorbed area 
per pit was higher at culture day 21 before treatment 
when compared with controls (p=0.0249) and decreased 
after therapy, reaching statistical significance at day 14 of 
Figure 1 Frequency of neutrophils and RANKL neutrophils. (A) Neutrophil frequency is significantly higher in patients 
with RA at baseline when compared with healthy donors (both frequency p=0.0110 and absolute number p=0.0032). (B) 
RANKL+neutrophil count is also higher at baseline when compared with healthy donors (p=0.0060). Neutrophil number is 
decreased after MTX and low-dose prednisolone treatment in patients with RA (absolute number only, p=0.0155). Each dot 
represents a sample and the line in healthy represents median. RA, rheumatoid arthritis; MTX, methotrexate; RANKL, receptor 
activator of nuclear factor-κβ ligand.
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culture (p<0.0001). Pit number at day 21 was positively 
correlated with tender joint count when all patients were 
analysed (r=0.499, p=0.042).
Bone turnover markers increased in patients with Ra at 
baseline and normalised after treatment
Serum level of sRANKL was higher in patiets with RA 
at baseline than in controls (p=0.0164; figure 4) and 
normalised after treatment. OPG levels did not change 
with treatment and was not different from controls. 
The sRANKL/OPG ratio was higher in patients when 
compared with controls and it was not affected by treat-
ment (p=0.0228 and p=0.0283, respectively). The ratio 
of CTX-I/P1NP positively correlated with DAS28 in 
patients before therapy (r=0.786, p=0.036). After treat-
ment with MTX and prednisolone, both CTX-I and P1NP 
negatively correlated with swollen joint count (r=−0.913, 
p=0.002 and r=−0.756, p=0.030, respectively).
disCussion
In this study, we have shown a decrease in the expression 
of surface markers on the different monocyte subpopu-
lations, as well as a decrease in OC activity, in patients 
with early RA treated with MTX and low-dose PDN. The 
characteristics of these patients were similar to other very 
early RA cohorts.23
Neutrophils are involved in RA pathology since the 
early phase of the disease and they express surface 
RANKL when activated.23–26 We showed that the number 
of neutrophils and RANKL+ neutrophils increased in 
untreated patients with RA when compared with controls 
and that, after treatment with MTX+PDN, the number of 
neutrophils decreased, reaching control values. Despite 
also being a source of RANKL,27–29 no differences were 
found in T or B lymphocyte RANKL surface expression 
before and after therapy.
Patients with RA have increased expression of 
monocyte surface markers of adhesion, activation and 
proteins involved in OC differentiation, like RANK 
and CD51/CD61 (αVβ3 integrin).
30–32 In our study, 
after exposure to MTX+PDN, CCR2, CD86, CD11b and 
RANK expression reduced in several monocyte subpop-
ulations, reaching normal expression levels. Dendritic 
cells, also present in circulation, express CD14, CD16 
and CD8633 34 and can also differentiate into OC.35 36 
These cells were also represented in the CD14/CD16 
subpopulations of monocytes since we did not exclude 
them. It was previously shown that CCR2 is upregulated 
in monocytes and T cells in patients with RA. In vivo 
studies have shown that this surface marker is involved 
in recruitment and activation of monocytes in response 
to monocyte chemoattractant protein-1 (MCP-1).37 38 
CD86 is a costimulatory molecule involved in the anti-
gen-presenting process and it has been shown to have 
an important role in T cells activation in RA synovia.33 
CD11b expression is increased in RA monocytes, 
promoting their binding and migrating properties and 
it has been shown that corticosteroid therapy decreases 
CD11b expression.39–41 These surface molecules 
(CCR2, CD86 and CD11b) are important in migration, 
Figure 2 Phenotype of monocyte subpopulations. (A) Classical subpopulation phenotype, (B) intermediate subpopulation, (C) 
non-classical subpopulation phenotype. Before treatment there was higher expression of CCR2 in classical and intermediate 
subpopulations, HLA-DR and CD86 in classical subpopulation, CD51/CD61 in the intermediate subpopulation, CD11b in non-
classical subpopulation and RANK both in intermediate and non-classical subpopulations. HLA-DR expression remained higher 
in patients after treatment when compared with controls. CCR2, CD86, CD11b and RANK were decreased in the referred 
populations after treatment. *p<0.05, **p<0.01. Each dot represents a sample and the line in healthy represents median. 
MFI, median fluorescence intensity; CCR2, C-C chemokine receptor type 2; HLA, human leucocyte antigen; RANK, receptor 
activator of nuclear factor-κB; MTX, methotrexate.
 on 20 F










pen: first published as 10.1136/rm




6 Perpétuo iP, et al. RMD Open 2017;3:e000365. doi:10.1136/rmdopen-2016-000365
RMD Open
activation and promotion of inflammation contrib-
uting to the continuous inflammatory infiltrate in the 
synovia. After therapy with MTX and corticoids, these 
surface markers were reduced in line with a decrease of 
swollen and tender joints.
We verified that the serum sRANKL/OPG ratio 
increased in RA, as previously described.42 After treat-
ment with MTX and low-dose PDN, the sRANKL/OPG 
ratio decreased. MTX has been recently associated 
with both reduction of the RANKL/OPG ratio and of 
Figure 3 Functional assays in differentiated OC. (A) No differences in OC number/mm2 or in pit number were found. 
Percentage of resorbed area was higher in patients at baseline at culture day 14 and 21 when compared with controls. 
Resorbed area per pit was lower at culture day 14 when compared with patients at baseline. At culture day 21, patients with RA 
at baseline had higher resorbed area per pit than controls. Dots and lines represent median and IQR. (B) Representative images 
of resorption pit assay in all groups at culture day 21; scale bar represents 100 μm. d, day; OC, osteoclast; RA, rheumatoid 
arthritis.
Figure 4 Serum sRANKL and OPG levels in healthy donors and patients with RA at baseline and after MTX and low-dose 
prednisolone treatment. Both sRANKL and the sRANKL/OPG ratio increased in patients at baseline when compared with 
healthy donors. There were no differences in circulating OPG level before and after treatment or when compared with controls. 
The sRANKL/OPG ratio remained significantly higher after treatment. Each dot represents a sample and the line in healthy 
represents median. sRANKL, soluble receptor activator of nuclear factor-κB ligand; OPG, osteoprotegerin; RA, rheumatoid 
arthritis.
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dickkopf-1 levels43 and it has been previously shown that 
MTX directly inhibits osteoclastogenesis in vitro in syno-
vial fibroblasts and PBMC cocultures by downregulating 
RANKL expression on synovial fibroblasts, but no effect 
on RANK expression was found.44 45
Finally, RANK is the essential receptor for monocyte 
differentiation in OC, it is upregulated in patients with RA 
and has been implicated in RA bone loss, both systemic 
and locally.42 We propose that the decrease in monocyte 
migration/adhesion molecules and downregulation of 
RANK expression after therapy decrease the osteoclas-
togenic potential of these cells. In fact, MTX-treated 
patients with RA reached the maximum OC number later 
than untreated patients and also than controls and the 
resorbed area per pit decreased significantly after treat-
ment. This suggests that MTX+PDN have an important 
role in downregulating OC function, which we believe is 
at least partially through the decrease in RANK surface 
expression by monocytes.
In conclusion, our results suggest that the European 
League Against Rheumatism recommended treatment 
approach for patients with early RA (MTX combined 
with low-dose corticosteroids14) downregulates OC func-
tion, which we propose to occur through the decrease in 
RANK surface expression by monocytes.
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